Unknown

Dataset Information

0

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.


ABSTRACT: The standard of care for first-line therapy in diffuse large B-cell lymphoma (DLBCL) is the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen. For patients who fail to respond, have an incomplete response or relapse, numerous effective options exists besides salvage cisplatin-based regimen and autologous stem cell therapy. Even with this approach, the outcome remains very poor for this group of patients. The present case illustrates a 55-year-old woman diagnosed with DLBCL, who experienced an early incomplete response, later progression during treatment with the R-CHOP regimen. The patient received salvage therapy with rituximab, cisplatin and gemcitabine, again with an incomplete response. The patient declined consideration for stem cell therapy. Her disease progressed and she enrolled in the present phase I trial using azacitadine priming and nanoalbumin-bound (nab)-paclitaxel. After three cycles, follow-up positron emission tomography/computed tomography revealed a complete response for the first time since her initial diagnosis and the patient has remained disease-free for >6 years. Azacitadine and nab-paclitaxel combination appeared to be an effective regimen for the treatment of this patient with refractory DLBCL.

SUBMITTER: Bowen RC 

PROVIDER: S-EPMC5245156 | BioStudies | 2017-01-01

SECONDARY ACCESSION(S): NCT00748553

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4877689 | BioStudies
2015-01-01 | S-EPMC4441579 | BioStudies
2011-01-01 | S-EPMC7394278 | BioStudies
2013-01-01 | S-EPMC3701613 | BioStudies
2019-01-01 | S-EPMC6601707 | BioStudies
2014-01-01 | S-EPMC4144364 | BioStudies
2015-01-01 | S-EPMC4702294 | BioStudies
2020-01-01 | S-EPMC7444590 | BioStudies
2016-01-01 | S-EPMC4908729 | BioStudies
2017-01-01 | S-EPMC5680759 | BioStudies